FTRE Stock Overview
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Fortrea Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.54 |
| 52 Week High | US$41.02 |
| 52 Week Low | US$24.93 |
| Beta | 0 |
| 1 Month Change | -6.48% |
| 3 Month Change | 19.25% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 24.72% |
Recent News & Updates
Fortrea: High Risk And Low Upside Potential
Feb 13Fortrea Holdings Inc.'s (NASDAQ:FTRE) Low P/S No Reason For Excitement
Feb 08
Shareholder Returns
| FTRE | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 5.7% | 3.7% | 2.2% |
| 1Y | n/a | 1.6% | 22.8% |
Return vs Industry: Insufficient data to determine how FTRE performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how FTRE performed against the US Market.
Price Volatility
| FTRE volatility | |
|---|---|
| FTRE Average Weekly Movement | 4.2% |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FTRE has not had significant price volatility in the past 3 months.
Volatility Over Time: FTRE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 17,730 | Tom Pike | www.fortrea.com |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Fortrea Holdings Inc. Fundamentals Summary
| FTRE fundamental statistics | |
|---|---|
| Market cap | US$3.25b |
| Earnings (TTM) | -US$3.40m |
| Revenue (TTM) | US$3.11b |
1.1x
P/S Ratio-986.8x
P/E RatioIs FTRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FTRE income statement (TTM) | |
|---|---|
| Revenue | US$3.11b |
| Cost of Revenue | US$2.59b |
| Gross Profit | US$520.40m |
| Other Expenses | US$523.80m |
| Earnings | -US$3.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -0.038 |
| Gross Margin | 16.74% |
| Net Profit Margin | -0.11% |
| Debt/Equity Ratio | 91.7% |
How did FTRE perform over the long term?
See historical performance and comparison